U.S. Markets closed

Here's Why You Should Invest in Masimo (MASI) Right Now

Zacks Equity Research
1 / 5

Is TD Ameritrade Holding (AMTD) Outperforming Other Finance Stocks This Year?

Is (AMTD) Outperforming Other Finance Stocks This Year?

Masimo Corporation MASI is currently one of the top-performing stocks in the MedTech space. The company’s strong fundamentals and global expansion are major positives at the moment.

Shares Up

In the past year, Masimo’s shares have rallied 7.8% against the industry’s decline of 2.5%.

The Zacks Rank #2 (Buy) stock currently has a Growth Score of A. This reflects possibilities of outperformance over the long haul. Our research shows that stocks with a Growth Score of A or B, when combined with a Zacks Rank #1 (Strong Buy) or #2 are better picks than most.

In the last 60 days, the Zacks Consensus Estimate for Masimo’s current-year earnings per share rose 1% to $2.89.

Masimo Corporation Price and Consensus


Masimo Corporation Price and Consensus | Masimo Corporation Quote

Let’s find out whether the bullish trend can sustain the stock’s impressive performance in the long run.

What Makes It an Attractive Pick?

Fundamental Growth Story

Masimo has been gaining from its strong fundamentals.

Since 2009, the company’s revenues grew to $798 million, at a CAGR of 10.9%.

Furthermore, Masimo’s earnings saw a CAGR of 15.5% to $2.82 since 2009.

Global Exposure

Masimo has significant international presence.

The California-based company’s flagship Eve application has been recently picked by the UAE Ministry of Health & Prevention (MOHAP). (Read more: MOHAP Selects Masimo's Eve for CCHD Screening in UAE)

Earlier this year, Masimo’s technologies were implemented by NU Hospitals, a Bangalore-based nephrology care center in India. (Read more: Masimo Products to Boost India-Based NU Hospitals' Systems)

Furthermore, in the last reported quarter, Masimo secured a substantial contract for its Rad-67 with blood transfusion centers in Valencia, Spain.

Raised Guidance

For 2018, revenues are estimated at $846 million, up from the previous projection of $836 million. The Zacks Consensus Estimate is pegged at $843.8 million, below the guided figure.

Adjusted earnings per share for 2018 are expected at $2.88, up from the previous guidance of $2.80. The Zacks Consensus Estimate is pinned at $2.89, slightly above the projected figure.

Other Key Picks

Some other top-ranked medical stocks are Genomic Health GHDX, Stryker Corporation SYK and Integer Holdings Corporation ITGR.

Genomic Health has an expected earnings growth rate of 187.5%. The stock flaunts a Zacks Rank #1. You can see the complete list of today’s Zacks #1 Rank stocks here.

Stryker has a projected long-term earnings growth rate of 9.7%. The stock carries a Zacks Rank #2.

Integer Holdings a long-term expected earnings growth rate of 15%. The stock carries a Zacks Rank #2.

Today's Stocks from Zacks' Hottest Strategies

It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.

And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.

See Them Free>>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Masimo Corporation (MASI) : Free Stock Analysis Report
Integer Holdings Corporation (ITGR) : Free Stock Analysis Report
Stryker Corporation (SYK) : Free Stock Analysis Report
Genomic Health, Inc. (GHDX) : Free Stock Analysis Report
To read this article on Zacks.com click here.